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Objective: To describe the association of calcitriol treatment with the change in parathyroid hormone
(PTH) and biochemical markers of bone disease in infants with metabolic bone disease of prematurity
(MBD) and secondary hyperparathyroidism.
Study design: This retrospective chart review examined serum intact PTH, serum calcium (Ca), serum
phosphorus (P), serum alkaline phosphatase (APA), urine calcium/creatinine (UCa/Cr), and tubular
reabsorption of phosphate (TRP) in 32 infants prior to and following calcitriol treatment for MBD with
PTH >100 pg/ml. 25-hydroxyvitamin D concentrations were recorded.
Results: Following calcitriol treatment, PTH decreased from median (min/max) 220 (115/593) to 25
(3/259) pg/ml, p < 0.001; Ca increased from 9.9 (8.9/10.7) to 10.3 (9.7/11.3) mg/dl, p < 0.001; P increased
from 4.3 (2.7/6.4) to 5.4 (2.9/7.4) mg/dl, p ¼ 0.001; and TRP increased from 81 (59/98) to 91.5 (78/98) %,
p ¼ 0.03. APA did not differ pre-treatment: 616 (209/1193) vs. post-treatment 485 (196/1229) U/L,
p ¼ 0.12. Vitamin D deﬁciency was not present. Hypercalcemia with hypercalciuria occurred in 3/32
subjects, all normalized after dose reduction.
Conclusion: Improvements in MBD markers and lack of serious adverse effects suggest calcitriol may be a
treatment option in infants with MBD and secondary hyperparathyroidism.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Metabolic bone disease of prematurity (MBD), a term often used
interchangeably with osteopenia or biochemical rickets of prema-
turity, is deﬁned as decreased bone mineral content relative to the
expected content for an infant of comparable size or gestational age
in conjunction with biochemical or radiographic changes. MBD
remains a signiﬁcant health care concern amongst pre-term and
small for gestational age infants, as current reports indicate thatMetabolic Bone Disease; Ca,
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access article under the CC BY-NC-10e20% of extremely low birth weight (ELBW, birth weight
<1000 g) premature infants have radiographic evidence of rickets
[1]. This rate likely underestimates the true incidence of MBD of
prematurity as signiﬁcant loss of bone mineralization is needed
before characteristic radiographic changes are visible [2].
Strategies for preventing and treating MBD include fortiﬁcation
of breast milk and use of preterm formulas [3e5]. The recom-
mended intake of calcium and phosphorus is 150e220 mg/kg/day
and 75e140 mg/kg/day, respectively [3]. Unfortunately, in a sub-
population of neonates, introduction of fortiﬁed feeds is delayed or
contraindicated [e.g. those with necrotizing enterocolitis (NEC),
bowel resection, feeding intolerance] and these infants cannot
beneﬁt from increased calcium and phosphorus present in fortiﬁ-
cation. Additionally, while total parenteral nutrition (TPN) may
allow for achievement of normal biochemical status, it frequently
cannot provide sufﬁcient mineral replacement to match in utero
rates of mineral accretion.
Phosphorus deﬁciency from inadequate intake is the typical
mechanism underlying much MBD, and biochemical proﬁles often
demonstrate decreased serum phosphorus (P), elevated serumND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mone (PTH), normal or even increased serum calcium (Ca) through
increased 1,25 hydroxyvitamin D [1,25(OH)2D, calcitriol] production,
and enhanced renal tubular reabsorption of phosphate (TRP). How-
ever, in other infants, calcium deﬁciency is the overriding abnormal-
ity. This inadequate calcium intake prompts excess PTH secretion and
urinary phosphatewasting. The role of PTH inMBDof prematurity has
received limited attention: a case series of three subjects [6], a large
retrospective case series reporting PTH concentration before and after
calcium supplementation in infants with birth weight <1000 g [7],
and a recent prospective observational study comparing PTH with
APA as an early serologicmarker forMBD [8]. All studies suggest a role
for PTH in the screening of MBD of prematurity.
Calcitriol, the active form of vitamin D, has a number of direct
effects that make it an attractive treatment option in the setting of
MBDwith increased PTH including: 1) increasing intestinal calcium
and phosphorus absorption, 2) increasing renal calcium reabsorp-
tion, and 3) suppressing parathyroid gland PTH secretion via tran-
scriptional down-regulation. Calcitriol has a shorter half-life than
cholecalciferol (vitamin D3), requires neither hepatic conversion to
25-hydroxyvitamin D [25(OH)D] nor its renal activation, and can be
administered either enterally or intravenously. Calcitriol used for
treatment of MBD has not been extensively studied. In a case report
of two infants with MBD, calcitriol treatment decreased serum APA
without adverse outcomes [9].
This retrospective study reports the use of calcitriol in addition
to routine nutritional management in a series of premature infants
with MBD and secondary hyperparathyroidism. The aim is to
describe the change in PTH and other biochemical markers of MBD
following initiation of calcitriol.
Case report
Patient Z was a 3½ month old preterm infant born at 26 weeks
gestationwith birth weight 800 g to a mother with HELLP syndrome
and pre-eclampsia. Patient Z was referred to The Children’s Hospital
of Philadelphia (CHOP) for NEC requiring multiple bowel resections.
Patient Z’s course was complicated by short bowel syndrome,
chronic lung disease, and TPN cholestasis. Medications included
caffeine, furosemide, and cholecalciferol. Feeding history was
notable for prolonged TPN requirement with only intermittentFigure 1. Patient Z’s biochemical markers of boperiods of full enteral feeds. The Bone Health team, a multidisci-
plinary team consisting of endocrinology, pharmacy, and nutrition,
was consulted after a right humerus fracture was discovered. At the
initial evaluation (day of life, DOL 110), Patient Z was receiving TPN
with 40 mg/kg/day elemental calcium, 63 mg/kg/day phosphorus,
and 520 IU/day cholecalciferol. Initial laboratory evaluation revealed
normal albumin-corrected Ca ¼ 9.5 mg/dL (2.4 mmol/L), decreased
P ¼ 2.7 mg/dL (0.87 mmol/L), elevated APA¼ 1190 U/L, elevated PTH
320 pg/ml, normal 25(OH)D ¼ 45 mg/dL (112 mmol/L), decreased
TRP ¼ 76%, and normal UCa:Cr ¼ 0.05 mg/mg. Calcitriol 0.1 mcg/kg/
day was initiated on DOL 115. Enteral feeds were started approxi-
mately 10 days later and slowly advanced with full unfortiﬁed feeds
being achieved by DOL 210 with fortiﬁcation by DOL 217. Calcitriol
dosewas decreased as feeds andmineral supplementation advanced
and furosemide was discontinued (Fig. 1). During the course of
treatment, intact PTH and APA concentrations decreased, while
serum calcium, phosphorus, and urinary TRP increased. Hypercal-
cemia (Ca ¼ 11.1 mg/dl) occurred without hypercalciuria, and
resolved with dose reduction (0.025 mcg/kg/day). Patient Z was
discharged home at 7 months of life (4 months after calcitriol was
started) and continued on low dose calcitriol for another year.
Methods
This studywas conducted through the Division of Endocrinology
at The Children’s Hospital of Philadelphia. The institutional review
board approved the study.
Study design
For this retrospective chart review, pharmacy records were
queried to identify infants prescribed calcitriol in the Neonatal
Intensive Care Unit (NICU) between July 1, 2009 and May 1, 2013.
Subjects
Infants were included for gestational age less than 37 weeks,
radiographic evidence of bone demineralization (as reported by
radiology, typically incidental ﬁnding on ﬁlms obtained for other
purposes), PTH concentration >100 pg/ml, and calcitriol treatment
between 1 and 12 months after birth. Exclusion criteria includedne disease during treatment with calcitriol.
Table 1
Subject characteristics (N ¼ 32)
Median (min, max)
Gestational age (weeks) 25 (23, 33)
Birth weight (grams) 692 (380, 1191)
Age at calcitriol start (days) 97 (47, 147)
Calcium intake (mg/kg/day) 40 (20, 243)
Phosphorus intake (mg/kg/day) 70 (19, 135)




TPN use 23 (73)
Use of bone adverse medications 29 (90)
TPN cholestasis 8 (25)
Liver failure 1 (3)
NEC (medical or surgical) 10 (31)
Other bowel surgery 9 (28)
Vitamin D deﬁcient (<20 mg/dL) 0 (0)
Vitamin D sufﬁcient (>30 mg/dL) 25 (78)
Calcium intake below 150 mg/kg/daya 27 (84)
Phos intake below 75 mg/kg/daya 20 (62)
Vitamin D intake below 200 IU/daya 4 (12.5)
a Calcium, phosphorus, and Vitamin D intake at time of calcitriol initiation.
Table 2







S.E. Rustico et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 14e2016signiﬁcant renal insufﬁciency, suspected vitamin D metabolism
defect, congenital parathyroid hormone defect, and lack of PTH
monitoring after calcitriol initiation.
The Children’s Hospital of Philadelphia (CHOP) management of MBD
of prematurity
The standard of care of MBD includes maximizing mineral
intake with early feeds, fortiﬁcation, and direct mineral supple-
mentation. In those neonates 1) unable to receive such standard
care due to intolerance or other restrictions and 2) who have PTH
>100 pg/ml, calcitriol has been used as adjunct treatment. This
concentration of PTH was chosen as this value is approximately
twice the upper limit for pediatric ranges (Immunolite 2000 assay).
Data collection
Data collected included basic demographics (date of birth, gesta-
tional age, birth weight, sex), coexisting medical problems, medica-
tions, intact PTH, serum Ca, serum albumin, serum P, serum creatinine
(Cr), serummagnesium (Mg), APA, urine Ca, urine P, urine Cr, 25(OH)D,
1,25(OH)2D, feeding/nutrition regimen, calcium intake (mg/kg/day),
phosphorus intake (mg/kg/day), vitamin D intake (IU/day), calcitriol
dose (mcg/kg/day) route of administration, and corresponding dates.
Biochemistry (Ca, P, APA,Mg, Cr, urine P, urine Cr, urine Ca) resultswere
recorded for the14daysprior to baselinePTHaswell as the7preceding
days and 7 days following any subsequent PTH measurement.
Radiographic description of bone disease as reported by the
radiologist was also recorded:
 Grade 1 e Loss of dense white lines at metaphyses, increased
submetaphyseal lucency, and/or thinning of cortex
 Grade 2e Any changes of Grade 1 plus irregularity and fraying of
the metaphyses, or with splaying or cupping
 Grade 3 e Any changes of Grade 1 with evidence of fracturesTPN exclusive (n ¼ 17) 40 (20, 60) 68 (21, 94) 260 (120,400)
TPN þ feed (n ¼ 6) 45 (37, 155) 75 (19, 95) 316 (6,481)
Unfortiﬁed feeds (n ¼ 3) 40 (40, 138) 21 (20, 47) 410 (73,419)
Fortiﬁed feeds (n ¼ 6) 168 (114,243) 88 (61, 135) 597 (193, 866)
All combined (n ¼ 32) 40 (20, 243) 70 (19, 135) 273 (6, 866)
a Results reported as median (min, max).Assays and analyses
Serum intact PTH values were measured using the immunoassay
system IMMUNOLITE2000 (SiemensHealthcareDiagnostics,Deerﬁeld,IL). Reference ranges for intact PTH are pediatric speciﬁc reference
range (9 e 56 pg/ml). Serum Ca, P, APA, Mg, albumin, and urine elec-
trolytes were measured with a Microslide chemistry system using
Vitros 5600 and Vitros 5,1 (Ortho Clinical Diagnostics, Raritan, NJ).
Data analyses
Biochemistry results obtained simultaneously with PTH were
used. For cases in which biochemistry was not obtained simulta-
neously with the baseline PTH, the average of two weeks of
biochemistry data obtained prior to calcitriol initiation was used.
For subsequent PTH values for which concomitant biochemistry
were not available, the ﬁrst set of biochemistry data that were
obtained within the ensuing 7 days were used.
Values above or below the limit of detection were substituted
with the value at the level of detection (e.g. PTH <3 pg/ml became
2.9 pg/ml and APA >1500 U/L became 1501 U/L). Calcium is re-
ported as albumin-corrected calcium using the formula: 0.8  (4 g/
dl  albumin) þ Serum Ca. Vitamin D deﬁciency was deﬁned as
25(OH)D < 20 mg/dl.
Day of life and days after calcitriol initiation were calculated.
Because frequency of laboratory evaluations varied among patients,
the time frame following calcitriol initiation was expressed in two-
week intervals.
Continuous data were presented as median (minimum/
maximum); categorical data were presented as proportions. Non-
normally distributed continuous data were analyzed using Wil-
coxon Sign Rank Test. Statistical analyses were performed with Stata
version 13 (Stata Corp, College Station, TX) and p-value <0.05 was
used to indicate signiﬁcance.
Results
Subject characteristics
Thirty-two neonates met inclusion and exclusion criteria
(Table 1). Two neonates were excluded for renal failure, and one
was excluded for PTH not measured after calcitriol initiation. Cal-
citriol was started no earlier than 6weeks after birth. Many subjects
(53%) had at least one fracture identiﬁed during the hospitalization.
Most were on bone adverse medications (i.e. loop diuretics,
caffeine, glucocorticoids). Vitamin D deﬁciency was not present.
Most subjects were receiving TPN (73%) when calcitriol was initi-
ated. Most subjects were below the recommended intake of cal-
cium (<150 mg/kg/day) and phosphorus (<75 mg/kg/day). Those
on TPN were receiving less calcium compared to those on fortiﬁed
feeds (Table 2).
Calcitriol starting dose, median (min/max), was 0.05 (0.03/0.1)
mcg/kg/day. Median dose throughout treatment was 0.08 (0.02/
0.2) mcg/kg/day. Treatment was continued for a median of 207
(17/581) days. Thirteen (40%) subjects were started on enteral
calcitriol and nineteen (60%) were started on intravenous
calcitriol.
Figure 2. PTH trend on calcitriol for 32 subjectsa,b.
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PTH prior to calcitriol initiation remained steadily elevated
(Fig. 2). Following calcitriol treatment, PTH decreased (Table 3). PTH
reached its nadir on average by 61 (4/487) days. PTH normalized
(PTH <55 pg/ml) on average by 38 (8/487) days.
Serum Ca (albumin-corrected), serum P, and TRP increased after
calcitriol treatment (Table 3, Fig. 3). Serum APA and UCa:Cr did not
differ compared to pretreatment values.
Nutritional intake
Calcium intake increased after calcitriol initiation, whereas
phosphorus intake remained stable around 75 mg/kg/day (Fig. 4).
Prior to initiation of feeds, the phosphorus content exceeded cal-
cium content when given via the parenteral route (Table 2).Table 3
PTH and biochemistry change from baseline to PTH nadir
Baseline At PTH
























Data shown is median and (min, max).Biochemistry based on radiographic grade
Compared to Grade 1 radiographic ﬁndings, those with Grade 3
had higher APA, but no signiﬁcant difference in Ca, P, or PTH
(Table 4).
Complications
PTH suppression (<10 pg/ml) was found in 8/32 subjects, but
calcitriol had already been discontinued in three of those subjects
when PTH suppression occurred. In the ﬁve subjects with PTH
<10 pg/ml while on calcitriol treatment, PTH suppression occurred
122 (54/228) days post treatment initiation. Hypercalciuria (UCa/
Cr > 1 mg/mg) was found in 9/32 subjects. In those neonates with
hypercalciuria, ﬁve were on loop diuretics and/or caffeine at
the time of hypercalciuria. Hypercalcemia (Ca >11 mg/dl) wasnadir Difference p-value
259) 181 (69, 584)
n ¼ 32
<0.001
.7, 11.3) þ0.56 (0.66, 1.55)
n ¼ 26
<0.001
, 7.4) þ1.1 (1.5, 3.85)
n ¼ 29
0.001
96, 1229) 112 (920,680)
n ¼ 27
0.12
8, 98) þ7.7 (9.7, 33)
n ¼ 10
0.03
.04, 1.7) 0.06 (0.52, 1.6)
n ¼ 14
0.87
Figure 3. APA, TRP, Calcium, and Phosphorus trend (N)a.
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occurred with hypercalciuria. However, in general, their PTH was
not suppressed: 15.6 pg/mL (6.1/26). The combination of hyper-
calciuria and hypercalcemia normalized after dose reduction. No
nephrocalcinosis was reported, but ultrasound was not performed
routinely.
Discussion
In this retrospective study, calcitriol treatment was associated
with PTH reduction in premature infants with MBD and secondary
hyperparathyroidism. This decline was associated with improve-
ments in urinary phosphate wasting and serum phosphorus, but
decrease in alkaline phosphatase was not consistent. Our ﬁndings
suggest that in a subset of neonates with MBD in whom calcium
deﬁciency is the major issue and in whom limited means to replace
calcium are available, pharmacologic treatment with calcitriol is a
potential option.
While calcitriol is the active form of vitamin D, its use was not
based on vitamin D deﬁciency as none of the subjects were deﬁ-
cient. Absence of hypovitaminosis D in our cohort is consistent with
other reports of normal 25(OH)D concentrations in the majority of
cases of MBD, and the ﬁnding of similar 25(OH)D concentrations in
preterm infants with and without rickets [10]. Instead, calcitriol
was chosen because at pharmacologic doses it appears to directly
suppress PTH secretion, thereby decreasing PTH-mediated urinary
phosphorus wasting and bone resorption. Calcitriol may provide
some beneﬁt in increasing intestinal calcium and phosphorus ab-
sorption. Importantly, preterm infants can require very smallcalcitriol doses which may only measure out to 0.05e0.1 mL (1e2
drops of drug according to United States Pharmacopeia measure-
ments). Due to the signiﬁcant binding of calcitriol to plastic [11], a
large percentage of a dose could be lost to adsorption. Diluting
enteral doses being administered via feeding tubes with additional
water and ﬂushing with twice the volume of the tube to ensure the
total dose is administered may be reasonable. Moreover, calcitriol
can be given intravenously; intravenous and enteral doses are
equivalent.
In a similar retrospective study, Moreira et al. found elevated
PTH (>88 pg/ml) in 85% of preterm ELBW infants with evidence
of bone demineralization on x-ray (n ¼ 66). These subjects were
treated with oral calcium carbonate 100 mg/kg/day, and a
reduction in PTH was found after 6 weeks [7]. Certainly opti-
mizing calcium intake is ideal, but oral calcium supplementa-
tion is not a viable or effective treatment option for many
patients with severe bowel disease/malabsorption. Moreover,
delivery of additional calcium and phosphorus is often not
possible with TPN alone due to limits with precipitation and
stability of TPN formulation. Underscoring the feeding limita-
tions and the high rate of TPN dependence in our study popu-
lation, calcium intake was below the limits of recommended
intake. Importantly, in our cohort, prescribed parenteral phos-
phorus often exceeded the prescribed calcium; presumably this
imbalance arose to manage low serum phosphorus concentra-
tions. The extent to which this enhanced phosphorus delivery
directly stimulated PTH secretion [12] in the presence of
hypophosphatemia is not known but may need to be considered
in such clinical situations.
Figure 4. Calcium and Phosphorus intakea,b.
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bone mineral outcomes cannot be strictly attributed to calcitriol
therapy. Improved calcium delivery that occurred either concomi-
tantly with or following calcitriol initiationmay have contributed to
these ﬁndings. However, prior to calcitriol, PTH remained persis-
tently elevated and declined by the ﬁrst 2 week interval afterTable 4
Biochemistry by bone class







(class 1 vs 3)
PTH (pg/ml)
Median 245 167 203 0.5
Min, max (115, 561) (143, 593)
Caa (mg/dl)
Median 10.1 10.2 9.6 0.22
Min, max (8.9, 10.7) (9, 10.5)
Phos (mg/dl)
Median 4.3 4.8 4.3 0.34
Min, max (3.3, 6.4) (2.7, 5.9)
APA (U/L)
Median 489 212 791 0.04
Min, max (209, 1042) (279, 1193)
a Albumin-corrected calcium.calcitriol initiation. This decline occurred without substantial
change in calcium intake.
This study also presents support for the use of TRP and PTH as
screening tools for MBD. TRP is elevated in nutritional phosphate
deﬁciency, but low in the setting of renal tubular damage as well as
hyperparathyroidism. Thus, if TRP is low, PTH can be used to
distinguish hyperparathyroidism from primary renal phosphate
wasting arising from tubular injury. The conﬁnes of using APA to
diagnose or guide management of MBD are well recognized. In this
cohort, APAwas >350 U/L in over 80% and >500 U/L in over 60%. In
general, APA decreased over time except in nine subjects in whom
APA was <500 U/L at baseline. In the remaining four, APA essen-
tially remained unchanged or increased slightly (data not shown);
the extent to which this lack of improvement reﬂects underlying
cholestasis cannot be assessed from this study.While APA>1000 U/
L is sensitive for diagnosing MBD [1], our median APA was much
lower for all classes of MBD radiographic description. In this study,
MBD was largely deﬁned by presence of radiological changes, but
the explanation for the lower than expected APA levels in a subset
of subjects with MBD cannot be determined by this study. This
relationship between APA and PTH could be examined in future
studies of MBD.
This retrospective study has several additional limitations. In the
absence of a control group, the extent to which PTH would have
S.E. Rustico et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 14e2020improved in the absence of calcitriol cannot be estimated. In the 8
subjects for whom PTH was monitored before treatment, the PTH
did not generally decrease prior to calcitriol. Additionally, PTH
>100 pg/ml was arbitrarily set as representing a hyperparathyroid
state. Moreira et al. used PTH>88 pg/ml to deﬁne hyperparathy-
roidismwhen initiating treatment with calcium, but found in a later
study that PTH>180 pg/ml at 3 weeks of life was useful in detecting
severe MBD [7,8]. The exact threshold for PTH has yet to be deﬁned
in neonates and is worthy of further study. 1,25(OH)2D levels were
not routinely measured and, thus, the relationship between PTH
and 1,25(OH)2D, if any, in our subjects with MBD cannot be evalu-
ated. In vitamin D deﬁciency, 1,25(OH)2D levels can be low, normal,
or elevated, and in preterm infants, reference data are not available.
Future studies examining the contribution of 1,25(OH)2D concen-
tration will likely provide insight into the pathophysiology of MBD
at least in a subset of patients. Timing of labs was not consistent
among patients, and data were not always available simultaneous
with the PTH concentration. Nutritional data were examined on a
day that corresponded with labs, but may not reﬂect the intake
from the preceding weeks.
Complications may be underestimated as biochemistry labs,
particularly urine studies, and renal ultrasounds were not routinely
obtained. The extent to which calcitriol impacts clinically relevant
outcomes (incidence of fractures, DXA scores, quality of life scores)
beyond laboratory markers of MBD is not clear. Radiographic ﬁlms
were not followed over time, and no protocol for radiographic
follow-up in MBD currently exists. Finally, the prevalence of frac-
tures, GI disturbances, and other health issues in this cohort from a
quaternary care NICU with a large surgical referral base was quite
high. These comorbidities distinguish this neonatal population
from the more typical preterm infants who do not face such chal-
lenges. Thus, while this study was conducted in a relatively criti-
cally ill population, it provides a potential treatment option for this
“less typical” NICU population in whom MBD in the setting of
secondary hyperparathyroidism may be more problematic.Conclusion
Overall improvements in MBDmarkers suggest calcitriol may be
a viable option in patients with severe bone disease complicated by
secondary hyperparathyroidism, in particular when other treat-
ment options are not available. This study highlights the need for
clinical trials to compare markers of bone disease, clinical outcome,and adverse effects in those managed with routine treatment alone
versus those in whom calcitriol is used as an adjunct.
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